Evidence map›Paper›PMID 37158739›Full record

ArticleMicrobiology spectrum2023

Susceptibility of Ugandan Plasmodium falciparum Isolates to the Antimalarial Drug Pipeline.

Oriana Kreutzfeld, Patrick K Tumwebaze, Martin Okitwi, Stephen Orena, Oswald Byaruhanga, Thomas Katairo, Melissa D Conrad, Stephanie A Rasmussen, Jennifer Legac, Ozkan Aydemir and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Antimicrobial agents and chemotherapy · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 4 countries.

Oriana KreutzfeldUniversity of California, San Francisco, San Francisco, California, USA.ORCID 0000-0003-2026-345X
Patrick K TumwebazeInfectious Diseases Research Collaboration, Kampala, Uganda.
Martin OkitwiInfectious Diseases Research Collaboration, Kampala, Uganda.
Stephen OrenaInfectious Diseases Research Collaboration, Kampala, Uganda.
Oswald ByaruhangaInfectious Diseases Research Collaboration, Kampala, Uganda.
Thomas KatairoInfectious Diseases Research Collaboration, Kampala, Uganda.
Melissa D ConradUniversity of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-9984-8030
Stephanie A RasmussenDominican University of California, San Rafael, California, USA.
Jennifer LegacUniversity of California, San Francisco, San Francisco, California, USA.
Ozkan AydemirProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
David GiesbrechtBrown University, Providence, Rhode Island, USA.
Barbara ForteWellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, United Kingdom.
Peter CampbellWellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, United Kingdom.
Alasdair SmithWellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, University of Dundee, Dundee, United Kingdom.
Hiroki KanoMitsubishi Tanabe Pharma Corporation, Yokohama, Japan.
Samuel L NsobyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Benjamin BlascoMedicines for Malaria Venture, Geneva, Switzerland.
Maelle DuffeyMedicines for Malaria Venture, Geneva, Switzerland.
Jeffrey A BaileyBrown University, Providence, Rhode Island, USA.
Roland A CooperDominican University of California, San Rafael, California, USA.ORCID 0000-0002-8437-9382
Philip J RosenthalUniversity of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-7953-7622
Infectious Diseases Research Collaboration · UGUniversity of California, San Francisco · USUniversity of Dundee · GBBrown University · USDominican University of California · USMedicines for Malaria Venture · CHMitsubishi Tanabe Pharma CorporationUniversity of Massachusetts Chan Medical School · US

Funding

Resistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4M
Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipelineR01AI139179 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Philip Jon Rosenthal · 2018 to 2026
$6.3M
NIAID NIH HHS R01 AI075045NIAID NIH HHS R01 AI139179
6 · The paper itself

Abstract

Malaria, especially Plasmodium falciparum infection, remains an enormous problem, and its treatment and control are seriously challenged by drug resistance. New antimalarial drugs are needed. To characterize the Medicines for Malaria Venture pipeline of antimalarials under development, we assessed the

Indexed as

AntimalarialsMalariaMalaria, FalciparumDrug ResistanceHumansLigasesPlasmodium falciparumProtozoan ProteinsUgandaAntimalarialsLigasesProtozoan Proteinsantimalarialsdrug resistancegenotypic identificationmalariaPlasmodium falciparumsusceptibility testingUgandan field isolates

Identifiers

PMID37158739
PMCPMC10269555
OpenAlexW4375956209

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.